1-4 of 4
Charles Michael Farber
Close
Sort by
Journal Articles

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Lihua E. Budde, MD PhD, Ahmad Halwani, Christopher A. Yasenchak, Charles Michael Farber, MD PhD, John M Burke, MD, Luis E. Fayad, MD, Beata Holkova, MD, Mark Knapp, MD, Kathryn S. Kolibaba, MD, Ranjana H Advani, MD, Stephen M Ansell, MD, PhD, Dipti Patel-Donnelly, MD, Habte A. Yimer, MD, Scott E. Smith, MD PhD, Moshe Yair Levy, MD, Mahesh Seetharam, MD, David Belada, MD PhD, Donald Brooks, MD, Edwin C. Kingsley, MD, Leonard M. Klein, Nina Wagner-Johnston, MD, Katherine Ruffner, Nancy L Bartlett, MD
Journal: Blood
Blood (2016) 128 (22): 104.
https://doi.org/10.1182/blood.V128.22.104.104
Published: 2016
Journal Articles

Relationship of JAK2 V617F Allelic Burden (AB) to Demographics, Disease Characteristics, and Response to Therapy in Persist-1, a Randomized Phase III Study of Pacritinib (PAC) Versus Best Available Therapy (BAT) in Patients (pts) with Primary and Secondary Myelofibrosis (MF)

Alessandro M. Vannucchi, Adam Mead, Miklos Egyed, Anita Szoke, Aleksandr Suvorov, Andrew Perkins, Jiri Mayer, Peter Ganly, Harry C. Schouten, Patrizia Tosi, Charles Michael Farber, Pierre Zachee, Jean-Jacques Kiladjian, Jyoti Nangalia, James P. Dean, Huafeng Zhou, Jack W. Singer, Ruben A. Mesa, Claire N. Harrison
Journal: Blood
Blood (2016) 128 (22): 3131.
https://doi.org/10.1182/blood.V128.22.3131.3131
Published: 2016
Journal Articles

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Inhye E Ahn, MD, Charles Michael Farber, MD PhD, Matthew Davids, MD, David L. Grinblatt, MD, Nicole Lamanna, MD, Anthony R. Mato, MDMSCE, Chadi Nabhan, MD MBA, FACP, Pavel Kiselev, PhD, Arlene S. Swern, PhD, E. Dawn Flick, RPh, MPH, ScD, Shriya Bhushan, PharmD, Kristen Sullivan, MBA, CCRA, Jeff Sharman, MD, Christopher R. Flowers, MD
Journal: Blood
Blood (2016) 128 (22): 3581.
https://doi.org/10.1182/blood.V128.22.3581.3581
Published: 2016
Journal Articles

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Jeff Sharman, MD, Matthew Davids, MD, Charles Michael Farber, MD PhD, David L. Grinblatt, MD, Neil E. Kay, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Chadi Nabhan, MD MBA, FACP, Kristen Sullivan, MBA, CCRA, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Christopher R. Flowers, MD
Journal: Blood
Blood (2016) 128 (22): 5941.
https://doi.org/10.1182/blood.V128.22.5941.5941
Published: 2016